Shares of Cell Therapeutics Inc (CTIC) have been halted this morning as the FDA Advistory Panel has now come out and rejected their lymphoma drug Pixantrone. When CTIC does reopen, I'd expect the stock to be cut in half atleast. CTIC still has a slight chance of approval when the FDA decision takse place at the end of April. Usually, the FDA will follow their panel ( today's vote ) but not always. With such a huge overwhelming vote, the FDA will likely to reject Pixantrone in April. Cell Therapeutics will probably need to raise more capital if it plans to continue Pixantrone.
US panel rejects Cell Therapeutics lymphoma drug
Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Stocks for 2010
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Showing posts with label ctic stock halted. Show all posts
Showing posts with label ctic stock halted. Show all posts
Monday, March 22, 2010
Monday, June 1, 2009
Cell Therapeutics CTIC Stock Halted - News Pending
This afternoon, 6/1/09, Cell Therapeutics, Inc. (CTIC) stock has been halted for news pending. The company will be presenting at the ASCO conference today so i'm assuming this has something to do with the halt.
I will post the news when it hits - you can discuss CTIC at www.stockstobuy.org or view our recent discussion thread.
CTIC News - June 1, 2009
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the 2009 American Society for Clinical Oncology ("ASCO") Annual Meeting for the first time since the top-line data were released, complete pivotal phase III results of CTI's EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial who presented the study at ASCO.
"Anthracycline-related drugs can be effective salvage agents in aggressive NHL, but our use of them is limited by the significant increase in risk of cardiac failure associated with high cumulative doses of these drugs," said Dr. Pettengell. "These results represent a breakthrough in that pixantrone could extend our ability to use a highly active anthracycline-like drug in such patients and deserves to be examined in anthracycline naive patients as a potential alternative to currently available standard anthracycline drugs." Full Article
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
I will post the news when it hits - you can discuss CTIC at www.stockstobuy.org or view our recent discussion thread.
CTIC News - June 1, 2009
Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that at the 2009 American Society for Clinical Oncology ("ASCO") Annual Meeting for the first time since the top-line data were released, complete pivotal phase III results of CTI's EXTEND (PIX 301) clinical trial of pixantrone (the "PIX 301 EXTEND trial") in relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") were presented by Principal Investigator, Ruth Pettengell, M.D. of St. George's Hospital, University of London, the lead investigator for the PIX 301 EXTEND trial who presented the study at ASCO.
"Anthracycline-related drugs can be effective salvage agents in aggressive NHL, but our use of them is limited by the significant increase in risk of cardiac failure associated with high cumulative doses of these drugs," said Dr. Pettengell. "These results represent a breakthrough in that pixantrone could extend our ability to use a highly active anthracycline-like drug in such patients and deserves to be examined in anthracycline naive patients as a potential alternative to currently available standard anthracycline drugs." Full Article
For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free
Subscribe to:
Posts (Atom)
